2. Immunology/Inflammation Vitamin D Related/Nuclear Receptor Metabolic Enzyme/Protease
  3. Interleukin Related LXR
  4. Taraxasterol

Taraxasterol is a pentacyclic triterpenoid compound isolated from Taraxacum mongolicum. Taraxasterol is an LXRα activator, with metabolic and anti-inflammatory effects. Taraxasterol may be used in research on immune-inflammatory diseases.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

CAS No. : 1059-14-9

Size Prix Stock Quantité
5 mg En stock
10 mg En stock
50 mg   Obtenir un devis  
100 mg   Obtenir un devis  

* Veuillez sélectionner la quantité avant d'ajouter des articles.

This product is a controlled substance and not for sale in your territory.

Avis client

Based on 4 publication(s) in Google Scholar

Other Forms of Taraxasterol:

Taraxasterol Related Antibodies

Top Publications Citing Use of Products
Cell Proliferation/Viability Assay
Cell Imaging/Staining
WB
Flow Cytometry
ELISA

    Taraxasterol purchased from MedChemExpress. Usage Cited in: Am J Cancer Res. 2024 Jun 15;14(6):2755-2769.  [Abstract]

    Dose response curve of Taraxasterol (5, 10, 30, 50, 70, 90, 100 μM) treatment in TC-1 and MLE-12 cells.

    Taraxasterol purchased from MedChemExpress. Usage Cited in: Am J Cancer Res. 2024 Jun 15;14(6):2755-2769.  [Abstract]

    Effect of Taraxasterol (10, 30, 50 μM) on cellular senescence determined by SpiDER-β-Gal staining.

    Taraxasterol purchased from MedChemExpress. Usage Cited in: Am J Cancer Res. 2024 Jun 15;14(6):2755-2769.  [Abstract]

    Effect of Taraxasterol (10, 30, 50 μM) on the expression of p16 and p21 determined by WB.

    Taraxasterol purchased from MedChemExpress. Usage Cited in: Am J Cancer Res. 2024 Jun 15;14(6):2755-2769.  [Abstract]

    Effect of Taraxasterol (10, 30, 50 μM) on cell cycle progression determined by Flow Cytometry.

    Taraxasterol purchased from MedChemExpress. Usage Cited in: Am J Cancer Res. 2024 Jun 15;14(6):2755-2769.  [Abstract]

    Taraxasterol (10, 30, 50 μM) decreased the secretion of IL-6/IL-1β as determined by ELISA analysis.

    Voir tous les produits spécifiques à Isoform Interleukin Related:

    Voir toutes les isoformes
    IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

    • Activité biologique

    • Pureté et documentation

    • Références

    • Avis client

    Description

    Taraxasterol is a pentacyclic triterpenoid compound isolated from Taraxacum mongolicum. Taraxasterol is an LXRα activator, with metabolic and anti-inflammatory effects. Taraxasterol may be used in research on immune-inflammatory diseases[1][2][3].

    In Vitro

    Taraxasterol (5-18 μg/ml, 1 h) inhibits vascular inflammation in human umbilical vein endothelial cells by activating LXRα [3].
    Taraxasterol (2.5-10 μg/ml, 24 h) exhibits anti-inflammatory effects on human osteoarthritic chondrocytes [5].
    Taraxasterol (114.68 μM, 24 h) has anti-metastatic effects on prostate cancer cells [6].
    Taraxasterol (5-18 μg/ml, 1 h) shows no cytotoxicity to human umbilical vein endothelial cells at concentrations below 15 μg/ml [3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Taraxasterol Related Antibodies

    Western Blot Analysis[5]

    Cell Line: Human umbilical vein endothelial cells (HUVECs)
    Concentration: 2.5, 5, 10 μg/ml
    Incubation Time: 24 h
    Result: Dose-dependently inhibited IL-1β-induced NF-κB activation.

    Cell Viability Assay[3]

    Cell Line: Human osteoarthritic chondrocytes
    Concentration: 5-18 μg/ml
    Incubation Time: 1 h
    Result: Did not have cytotoxic effects on HUVECs at the concentrations of 5, 10, and 15 μg/ml.
    Could decrease the viability of HUVECs at the concentration of 18 μg/ml.

    Cell Viability Assay[6]

    Cell Line: Prostate cancer cell lines (PC3 cells)
    Concentration: 1, 2, 4, 8, 16, 32, 64, 128 μM
    Incubation Time: 24, 48, 72 h
    Result: Reduced the survival rate of PC3 cells.

    Cell Invasion Assay[6]

    Cell Line: Prostate cancer cell lines (PC3 cells)
    Concentration: 114.68 μM
    Incubation Time: 24 h
    Result: Decreased the potential for cell invasion by 54%.
    In Vivo

    Taraxasterol (2.5, 5, and 10 mg/kg, i.p., 8 h) has a protective effect against acute lung injury in a lipopolysaccharide (HY-D1056)-induced acute lung injury mouse model[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Lipopolysaccharide (HY-D1056)-induced acute lung injury mouse model
    Dosage: 2.5, 5, and 10 mg/kg
    Administration: Intraperitoneal injection (i.p.), 8 h
    Result: Inhibited the phosphorylation of IκB-α, p65 NF-κB, p46–p54 JNK, p42–p44 ERK, and p38 caused by Lipopolysaccharide (HY-D1056).
    Masse moléculaire

    426.72

    Formule

    C30H50O
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    CC(C)([C@]1([H])CC[C@@]([C@](CC[C@@](CC2)3C)4C)5C)[C@@H](O)CC[C@]1(C)[C@@]5([H])CC[C@]4([H])[C@@]3([H])[C@H](C)C2=C
    Structure Classification
    Initial Source
    Livraison

    Room temperature in continental US; may vary elsewhere.
    Stockage

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    Solvant et solubilité
    In Vitro: 

    Ethanol : 4 mg/mL (9.37 mM; Need ultrasonic)

    DMSO : 1 mg/mL (2.34 mM; ultrasonic and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.3435 mL 11.7173 mL 23.4346 mL
    5 mM 0.4687 mL 2.3435 mL 4.6869 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Calculateur de molarité

    • Calculateur de dilution

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% EtOH    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 0.55 mg/mL (1.29 mM); Clear solution

      This protocol yields a clear solution of ≥ 0.55 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (5.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% EtOH    90% Corn Oil

      Solubility: ≥ 0.55 mg/mL (1.29 mM); Clear solution

      This protocol yields a clear solution of ≥ 0.55 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (5.5 mg/mL) to 900 μL Corn oil, and mix evenly.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  50% PEG300    50% Saline

      Solubility: 2.5 mg/mL (5.86 mM); Suspended solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Pureté et documentation

    Purity: 99.41%

    SDS (393 KB)

    COA (252 KB) HNMR (452 KB) RP-HPLC (220 KB) MS (88 KB)

    Instruction de manipulation (2659 KB)
    Références

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO / Ethanol 1 mM 2.3435 mL 11.7173 mL 23.4346 mL 58.5864 mL
    Ethanol 5 mM 0.4687 mL 2.3435 mL 4.6869 mL 11.7173 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Taraxasterol Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Taraxasterol1059-14-9Interleukin RelatedLXRILLiver X receptorInhibitorinhibitorinhibit

    Vos produits récemment consultés:

    Demande en ligne

    Your information is safe with us. * Required Fields.

    Nom du produit

    		  

    Requested Quantity *

    Nom du demandeur *

    		 

    Civilité

    Adresse e-mail *

    		 

    Numéro de téléphone *

    Department

    		 

    Nom de l'organisation *

    City

    État

    Country or Region *

    		      

    Remarques

    Bulk Inquiry

    Inquiry Information

    Nom du produit:
    Taraxasterol
    Cat. No.:
    HY-N1178
    Quantité:
    MCE Japan Authorized Agent:

    Avis client

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Nom du produit

    		  

    Lot #

    Nom du demandeur *

    		 

    Adresse e-mail *

    Numéro de téléphone

    		 

    Department *

    Nom de l'organisation *

    		 

    Country or Region *

    Remarques

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.